Opendata, web and dolomites

CINK TERMINATED

Advancing cancer immunotherapy using natural killer cells for hematological and metastatic cancers

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CINK project word cloud

Explore the words cloud of the CINK project. It provides you a very rough idea of what is the project "CINK" about.

limited    limits    expanded    cellular    expression    shp1    cytotoxicty    suppression    strategies    transplantation    types    intensively    treatment    sustained    ncf    rates    portion    combination    time    cells    date    leukemias    induction    heterogeneity    relapse    myeloma    frame    hematopoietic    benefit    impacted    combining    consequently    multiple    hematological    immunregulatory    ab    explore    aggressive    dependent    explored    cd16    mechanisms    hsct    express    adcc    stem    antibody    function    combine    unstable    translated    monoclonal    shown    nca    immunotherapy    improvement    efficacy    blockade    antibodies    stronger    cd137    lymphomas    ing    inhibitory    tremendously    versatility    limiting    adoptive    hypothesize    cell    action    anti    cancer    metastatic    coated    costimulation    evasion    cancers    activation    signals    fc    binding    transfer    clinic    amount    stimulating    il12    therapies    molecule    potentially    therapy    negatively    nk    tumor    mab    intrinsic   

Project "CINK" data sheet

The following table provides information about the project.

Coordinator
FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA 

Organization address
address: AVENIDA DE PIO XII 55
city: PAMPLONA
postcode: 31008
website: www.cima.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 158˙121 €
 EC max contribution 158˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-02-15   to  2020-02-14

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA ES (PAMPLONA) coordinator 158˙121.00

Map

 Project objective

The development of monoclonal antibodies (mAb) to target tumor cells has tremendously improve cancer immunotherapy and benefit the treatment of aggressive cancer such as some types of lymphomas, leukemias, multiple myeloma and metastatic cancers. One of the mechanisms of action is the induction of antibody-dependent cellular cytotoxicty (ADCC) through the activation of CD16 on NK cells after binding to the Fc portion of Ab-coated tumor cells. Therefore, strategies that combine NK cell activation and mAb therapy has been intensively explored. However, tumor heterogeneity and unstable expression of the targeted molecule in the tumor cells limits ADCC for mAb therapy resulting in cancer relapse. Furthermore, intrinsic NK immunregulatory mechanisms as well as NK-specific tumor evasion mechanisms have also negatively impacted the use of NK cell-based therapies. In this proposal we will explore the mechanisms involved in the reduced NK cell function (NCF) observed after ADCC and/or NK cell activation (NCA) in order to develop novel strategies to achieve a sustained and stronger NCF by combining stimulating signals with suppression of inhibitory signals such as costimulation via CD137 and IL12, or SHP1/2 blockade. We hypothesize that the adoptive transfer (AT) of NK cells expanded by this novel method will result in better anti-tumor responses after mAb therapy even in tumor cells that express limited amount of the target molecule and limiting consequently cancer relapse rates. Furthermore, due to the overall improvement on NCF, we expect that the combination of AT NK cells with hematopoietic stem cell transplantation (HSCT) will also increase anti-tumor responses; which efficacy up to date has shown to be rather limited. Given the versatility of our approach, this therapy can be used for the treatment of many cancers, but particularly hematological and metastatic cancers and potentially can be translated into the clinic in a short time frame.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CINK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CINK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

BrownianReactivation (2019)

Neural stochasticity and criticality in memory replay

Read More  

CarboPorph (2020)

Novel Cyclocarbon-Porphyrin Systems: Synthesis and Properties

Read More  

TIPTOP (2019)

Tensoring Positive Maps on Operator Structures

Read More